FGB: Fibrinogen beta chain
Cleaved by the protease thrombin to yield monomers which, together with fibrinogen alpha (FGA) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on FGB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Biciromab brallobarbital | Phase 1 | — | Antibody-drug conjugate | Binding agentFibrinogen beta chain binding agent | 0 |
- Congenital afibrinogenemia0.79
- Familial dysfibrinogenemia0.70
- Congenital fibrinogen deficiency0.62
- Familial hypodysfibrinogenemia0.60
- Cancer0.59
- Noonan syndrome0.53
- Hypertrophic cardiomyopathy0.50
- Costello syndrome0.50
- Hemorrhage0.49
- Recurrent thrombophlebitis0.46
- Deep vein thrombosis0.46
- Venous thromboembolism0.44
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2048, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P02675, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets